Printer Friendly

CellPoint plans to start patient recruitment for Phase 2b cardiovascular imaging study of Oncardia kits.

M2 PHARMA-May 20, 2019-CellPoint plans to start patient recruitment for Phase 2b cardiovascular imaging study of Oncardia kits

(C)2019 M2 COMMUNICATIONS

CellPoint, a biopharmaceutical company, announced on Friday that it plans to commence patient recruitment for its Phase 2b cardiovascular imaging study in patients suffering from coronary artery disease using the company's new one-vial Oncardia (ethylenedicysteine-glucosamine) kits.

The trial is being conducted on 60 patients in the United States.

99mTc-Oncardia is not a perfusion agent. It is being clinically studied as the first functional cardiovascular imaging agent that is target specific for myocardial ischemia.

One of the clinical objectives of the study is to demonstrate that the product can be effectively used where the patient does not need to be either physically or pharmacologically stressed for the study. If a rest only study is clinically validated, the product is claimed to have the potential to change the dynamic for how nuclear cardiac scans are performed. The product is for use with SPECT camera systems. CellPoint is also planning to clinically study the product for use with PET camera systems.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Article Type:Report
Date:May 20, 2019
Words:191
Previous Article:Eiger BioPharmaceuticals' David Apelian to step down.
Next Article:Takeda Pharmaceuticals awarded US FDA approval for GATTEX (teduglutide) for children with short bowel syndrome.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters